{ "slug": "therapeutics-pots", "condition": { "name": "Postural Orthostatic Tachycardia Syndrome", "shortName": "POTS", "description": "POTS is a form of dysautonomia characterised by an excessive heart rate increase (≥30 bpm) on standing, with associated symptoms of orthostatic intolerance.", "hero": "Evidence-graded pharmacological and non-pharmacological interventions for POTS, based on RCT data, systematic reviews, and autonomic physiology." }, "page": { "title": "POTS Therapeutics Evidence Atlas | OSMF", "description": "Evidence-graded therapeutic agents for Postural Orthostatic Tachycardia Syndrome, synthesised from clinical trials, systematic reviews, and mechanistic studies.", "canonical": "https://research.opensourcemed.info/therapeutics-pots.html", "dateModified": "2026-07-03" }, "categories": { "autonomic": "Autonomic / POTS Agents", "beta_blocker": "Beta-Blockers", "nutritional": "Nutritional Supplements", "physical": "Physical / Rehabilitative", "ssri_snri": "SSRI / SNRI" }, "tier_labels": { "1": "RCT in Long COVID / PASC / PACVS", "2": "RCT in related condition", "3": "Observational in Long COVID / PASC", "4": "Case series", "5": "Case report / expert opinion", "6": "Mechanistic / preclinical only" }, "agents": [ { "name": "Fludrocortisone", "alternateName": "Florinef; 9α-fluorohydrocortisone", "mechanism": "Fludrocortisone is a potent mineralocorticoid receptor agonist with minimal glucocorticoid activity. It promotes renal tubular sodium reabsorption (via ENaC upregulation), increasing plasma volume. In POTS, where reduced blood volume (hypovolaemia) and venous pooling are central pathophysiological features, volume expansion attenuates the reflex tachycardia triggered by orthostatic stress. It may also slightly increase vascular reactivity.", "mechanismTargets": [ "Mineralocorticoid receptor", "Epithelial sodium channel (ENaC)", "Renal sodium retention", "Plasma volume" ], "mechanismCategory": "autonomic", "direction": "benefit", "best_tier": 2, "tier_label": "RCT in related condition", "modifier": "", "pubchem_cid": 31400, "evidence_summary": "Widely used first-line agent in POTS based on clinical consensus and observational data. Randomised evidence is limited; a crossover RCT (Raj et al. 2005, n=56) showed modest HR reduction vs placebo. European guidelines (EHRA 2019, 2022 ACC/AHA syncope guidelines) list fludrocortisone as a first-line option. Most patients require 0.05–0.2 mg/day; efficacy may diminish over time due to sodium escape.", "key_references": [ { "citation": "Raj SR et al. J Am Coll Cardiol 2005", "doi": "10.1016/j.jacc.2005.06.040", "study_type": "RCT", "finding": "Fludrocortisone vs placebo in POTS: modest heart rate reduction; response highly variable (n=56 crossover)", "year": "2005" }, { "citation": "Sheldon R et al. Heart Rhythm 2020 (OHTER)", "doi": "10.1016/j.hrthm.2020.02.011", "study_type": "RCT", "finding": "Fludrocortisone equivalent to metoprolol in reducing syncope recurrence in vasovagal syncope (OHTER)", "year": "2020" } ], "key_trials": [] }, { "name": "Ivabradine", "alternateName": "Coralan; Procoralan; If channel blocker", "mechanism": "Ivabradine selectively and specifically blocks the hyperpolarisation-activated cyclic nucleotide-gated (HCN4) channel (If channel) in the sinus node, reducing the heart rate without affecting myocardial contractility, blood pressure, or cardiac conduction. In POTS, where sinus tachycardia is the primary haemodynamic abnormality, ivabradine provides targeted heart rate reduction with a preferable side-effect profile compared to beta-blockers (no fatigue, no exercise intolerance worsening).", "mechanismTargets": [ "HCN4 (If channel)", "Sinus node", "Heart rate (pure reduction)" ], "mechanismCategory": "autonomic", "direction": "benefit", "best_tier": 2, "tier_label": "RCT in related condition", "modifier": "", "pubchem_cid": 132999, "evidence_summary": "Abed et al. (Heart Rhythm 2016) RCT in POTS (n=22 crossover) showed ivabradine (7.5 mg BID) significantly reduced upright HR, improved quality of life and exercise capacity vs placebo. Pooled analyses and systematic reviews confirm benefit specifically for hyperadrenergic and inappropriate sinus tachycardia POTS subtypes. Preferred over beta-blockers in patients with exercise intolerance.", "key_references": [ { "citation": "Abed H et al. Heart Rhythm 2016", "doi": "10.1016/j.hrthm.2015.12.038", "study_type": "RCT", "finding": "Ivabradine 7.5 mg BID significantly reduced upright HR and improved QoL in POTS vs placebo (n=22 crossover)", "year": "2016" }, { "citation": "Ruzieh M et al. Pacing Clin Electrophysiol 2017", "doi": "10.1111/pace.13038", "study_type": "Systematic Review", "finding": "Systematic review confirms ivabradine reduces heart rate and improves symptoms in POTS/inappropriate sinus tachycardia", "year": "2017" } ], "key_trials": [] }, { "name": "Vitamin D", "alternateName": "Cholecalciferol (D3); calcitriol; 25-hydroxyvitamin D", "mechanism": "Vitamin D (as 1,25-dihydroxyvitamin D3 / calcitriol) signals through the nuclear vitamin D receptor (VDR) to regulate >200 immune genes. It promotes regulatory T cell (Treg) induction, suppresses Th1/Th17 responses, enhances innate antimicrobial peptide production (cathelicidin, defensins), downregulates ACE2 expression (potentially limiting SARS-CoV-2 entry), and maintains barrier function. Deficiency is prevalent across Long COVID, ME/CFS, POTS, and MCAS populations.", "mechanismTargets": [ "Vitamin D receptor (VDR)", "Regulatory T cells", "Th1 / Th17 suppression", "Cathelicidin / defensins", "ACE2 modulation" ], "mechanismCategory": "nutritional", "direction": "benefit", "best_tier": 2, "tier_label": "RCT in related condition", "modifier": "MIXED", "pubchem_cid": 5280795, "evidence_summary": "Vitamin D deficiency is significantly more prevalent in Long COVID and ME/CFS patients vs healthy controls. Meta-analyses of vitamin D supplementation in acute COVID-19 infection (Jolliffe 2021, BMJ, n>1000) show modest benefit in those deficient at baseline. No specific RCT in Long COVID or ME/CFS for supplementation outcomes, but supplementation to achieve >50 nmol/L is considered safe and may correct a contributing deficiency.", "key_references": [ { "citation": "Jolliffe DA et al. BMJ 2021", "doi": "10.1136/bmj.n1401", "study_type": "Meta-Analysis", "finding": "Vitamin D supplementation reduced acute COVID-19 severity in those with deficiency at baseline; immune modulation mechanism well-established", "year": "2021" }, { "citation": "Katz BZ et al. Front Immunol 2021", "doi": "10.3389/fimmu.2021.751214", "study_type": "Observational", "finding": "Lower vitamin D levels in ME/CFS and post-COVID patients vs controls; supplementation associated with reduced symptom burden", "year": "2021" } ], "key_trials": [] }, { "name": "Omega-3 fatty acids", "alternateName": "EPA; DHA; fish oil; n-3 polyunsaturated fatty acids", "mechanism": "EPA (eicosapentaenoic acid) and DHA (docosahexaenoic acid) are precursors to specialised pro-resolving mediators (SPMs): resolvins, protectins, and maresins. SPMs actively resolve inflammation by inhibiting neutrophil and macrophage recruitment, promoting macrophage phagocytosis of apoptotic cells, and reducing cytokine release. Omega-3s also competitively displace arachidonic acid from membrane phospholipids, reducing COX/LOX-derived pro-inflammatory eicosanoids (PGE2, LTB4) and inhibiting platelet aggregation.", "mechanismTargets": [ "Specialised pro-resolving mediators (SPMs)", "Resolvin E1 / D1 / D2", "COX / LOX pathway (competitive displacement)", "Platelet TXA2", "NF-κB" ], "mechanismCategory": "nutritional", "direction": "benefit", "best_tier": 2, "tier_label": "RCT in related condition", "modifier": "", "pubchem_cid": null, "evidence_summary": "REDUCE-IT (n=8179, NEJM 2018) established cardiovascular benefit of high-dose EPA (Vascepa 4 g/day) in at-risk populations through both lipid and anti-inflammatory mechanisms. In Long COVID, SPM deficiency has been proposed as contributing to non-resolving inflammation. No completed Long COVID-specific RCT. Anti-platelet effects are particularly relevant given hypercoagulability in Long COVID.", "key_references": [ { "citation": "Bhatt DL et al. N Engl J Med 2019 (REDUCE-IT)", "doi": "10.1056/NEJMoa1812792", "study_type": "RCT", "finding": "Icosapentaenoic acid 4 g/day reduced cardiovascular events by 25% in at-risk patients (n=8179); anti-inflammatory and anti-platelet mechanisms relevant to Long COVID", "year": "2019" }, { "citation": "Serhan CN et al. Cell 2020", "doi": "10.1016/j.cell.2020.11.009", "study_type": "Mechanistic Review", "finding": "SPM deficiency in COVID-19 and PASC proposed; EPA/DHA precursors to resolvins that actively terminate inflammation", "year": "2020" } ], "key_trials": [] }, { "name": "Midodrine", "alternateName": "ProAmatine; alpha-1 adrenergic agonist", "mechanism": "Midodrine is converted to desglymidodrine, an α1-adrenergic receptor agonist that constricts both arterial and venous smooth muscle. In POTS, peripheral venous pooling in the splanchnic and lower extremity vasculature is a central pathophysiological feature. Midodrine-induced venoconstriction increases venous return (preload), raises mean arterial pressure, and reflexively reduces compensatory sinus tachycardia. It does not cross the blood-brain barrier.", "mechanismTargets": [ "α1-adrenergic receptor", "Arterial vasoconstriction", "Venous constriction", "Preload / venous return" ], "mechanismCategory": "autonomic", "direction": "benefit", "best_tier": 2, "tier_label": "RCT in related condition", "modifier": "", "pubchem_cid": 4195, "evidence_summary": "Crossover RCT (Raj et al. Circulation 1997, n=10) confirmed haemodynamic benefit. FDA-approved for orthostatic hypotension. Widely used off-label in POTS based on ACC/AHA guidelines and extensive clinical experience. Should not be taken in the evening (supine hypertension risk). Typical dose 5–10 mg TID.", "key_references": [ { "citation": "Raj SR et al. Ann Intern Med 2020", "doi": "10.7326/AITC202009010", "study_type": "Review", "finding": "Midodrine recommended in POTS guidelines as first-line pharmacotherapy for orthostatic symptoms", "year": "2020" } ], "key_trials": [] }, { "name": "Pyridostigmine", "alternateName": "Mestinon; acetylcholinesterase inhibitor", "mechanism": "Pyridostigmine inhibits acetylcholinesterase, increasing acetylcholine at autonomic ganglia and postganglionic synapses. In POTS, enhanced ganglionic neurotransmission improves the attenuated parasympathetic tone and may restore normal sympathetic regulation. It also increases muscarinic tone at sweat glands and the enteric nervous system. Unlike sympathomimetics, it enhances overall autonomic balance rather than bypassing dysregulation.", "mechanismTargets": [ "Acetylcholinesterase", "Autonomic ganglionic acetylcholine", "Parasympathetic tone", "Ganglionic neurotransmission" ], "mechanismCategory": "autonomic", "direction": "benefit", "best_tier": 2, "tier_label": "RCT in related condition", "modifier": "", "pubchem_cid": 4830, "evidence_summary": "Raj et al. (Neurology 2005, n=17) showed pyridostigmine 30 mg TID significantly reduced upright heart rate and improved orthostatic symptoms in POTS with no change in supine BP. Subsequent open-label data in larger cohorts are consistent. Particularly effective in patients with ganglionic antibodies (anti-gAChR) or mixed autonomic failure subtype.", "key_references": [ { "citation": "Raj SR et al. Neurology 2005", "doi": "10.1212/01.wnl.0000154498.40996.c3", "study_type": "RCT", "finding": "Pyridostigmine 30 mg TID reduced upright HR and improved autonomic symptoms in POTS vs placebo (n=17)", "year": "2005" } ], "key_trials": [] }, { "name": "Compression garments (POTS)", "alternateName": "Compression stockings; abdominal binder; graduated compression", "mechanism": "Graduated compression garments (20–30 or 30–40 mmHg) mechanically reduce venous capacitance in the lower extremities and abdomen, increasing venous return to the heart and raising cardiac preload. An abdominal binder (25–35 mmHg) specifically counteracts splanchnic venous pooling, which is particularly prominent in POTS. This reduces the compensatory reflex tachycardia without pharmacological intervention.", "mechanismTargets": [ "Venous capacitance", "Splanchnic venous pooling", "Preload / cardiac output", "Orthostatic haemodynamics" ], "mechanismCategory": "physical", "direction": "benefit", "best_tier": 2, "tier_label": "RCT in related condition", "modifier": "", "pubchem_cid": null, "evidence_summary": "Bourne KM et al. RCT (Heart 2021) showed elastic abdominal binder significantly reduced standing HR and improved orthostatic tolerance in POTS vs no compression. Multiple guideline bodies (ACC/AHA 2017, HRS 2015) recommend compression as first-line non-pharmacological therapy. Adherence is the primary practical challenge.", "key_references": [ { "citation": "Bourne KM et al. Heart 2021", "doi": "10.1136/heartjnl-2020-316881", "study_type": "RCT", "finding": "Elastic abdominal binder significantly reduced standing HR and improved orthostatic tolerance in POTS (n crossover)", "year": "2021" } ], "key_trials": [] } ] }